HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7093-7102

  Ruan, Jing ^a   Song, Hua ^a   Qian, Qirong ^b   Li, Chao ^a   Wang, Kan ^a   Bao, Chenchen ^a   Cui, Daxiang ^a  

^a Shanghai Jiao Tong University   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CdTe quantum dot cluster; HER2 monoclonal antibody; In situ gastric cancer; RNase A; Target imaging; Therapy

Indexed keywords

BIODISTRIBUTIONS; CDTE; CDTE QUANTUM DOTS; CELL APOPTOSIS; GASTRIC CANCER CELLS; GASTRIC CANCERS; IN-SITU; IN-VIVO; MOUSE MODELS; NUDE MICE; PROTEIN SYNTHESIS; RNASE A; SURVIVAL TIME; TARGET IMAGING; TARGETED IMAGING; THERAPEUTIC EFFECTS; THERAPY;

CADMIUM TELLURIDE; CELL DEATH; MAMMALS; MONOCLONAL ANTIBODIES; NANOPROBES; SEMICONDUCTOR QUANTUM DOTS; TISSUE;

DISEASES;

CADMIUM TELLURIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; QUANTUM DOT; RIBONUCLEASE A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; MALE; MOUSE; NANOPROBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STOMACH CANCER; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOCOMPATIBLE MATERIALS; CADMIUM COMPOUNDS; CELL LINE, TUMOR; CYTOPLASM; DIAGNOSTIC IMAGING; HUMANS; MICE; MICE, NUDE; MICE, SCID; NANOTECHNOLOGY; NEOPLASM TRANSPLANTATION; QUANTUM DOTS; RECEPTOR, ERBB-2; RIBONUCLEASE, PANCREATIC; STOMACH NEOPLASMS; TELLURIUM; TIME FACTORS;

MUS MUSCULUS;

EID: 84864319347     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.053     Document Type: Article

References (52)

1. Hohenberger P., Gretschel S. Gastric cancer. Lancet 2003, 362:305-315.
2. Parkin D.M. International variation. Oncogene 2004, 23:6329-6340.
3. Parkin D.M., Bray F., Devesa S. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37:S4-66.
4. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J Gastroenterol 2006, 12:354-362.
5. Cui D.X., Zhang L., Yan X.J., Zhang L.X., Xu J.R., Guo Y.H., et al. A microarray-based gastric carcinoma prewarning system. World J Gastroenterol 2005, 11:1273-1282.
6. Xu J.R., Zhang L., Zhang L.X., Wang K., Chen J., Jia C.H., et al. Gene expression profiles of rodent atrophic gastritis induced by hot and salt water. Nano Biomed Eng 2011, 3:236-242.
7. Huang P., Xu C., Lin J., Wang C., Wang X., Zhang C., et al. Folic acid-conjugated graphene oxide loaded with photosensitizers for targeting photodynamic therapy. Theranostics 2011, 1:240-250.
8. Huang P., Bao L., Zhang C., Lin J., Luo T., Yang D., et al. Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials 2011, 32:9796-9809.
9. Tian B., Wang C., Zhang S., Feng L., Liu Z. Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide. ACS Nano 2011, 5:7000-7009.
10. Ruan J., Wang K., Song H., Xu X., Ji J., Cui D.X. Biocompatibility of hydrophilic silica-coated CdTe quantum dots and magnetic nanoparticles. Nanoscale Res Lett 2011, 6:1-13.
11. Ma L.L., Feldman M.D., Tam J.M., Paranjape A.S., Cheruku K.K., Larson T.A., et al. Small multifunctional nanoclusters (nanoroses) for targeted cellular imaging and therapy. ACS Nano 2009, 3:2686-2696.
12. 4 upconversion nanocrystals via an OA/ionic liquid two-phase system for in vivo dual-modality imaging. Adv Funct Mater 2011, 21:4470-4477.
13. Wang K., Ruan J., Qian Q., Song H., Bao C., Zhang X., et al. BRCAA1 monoclonal antibody conjugated fluorescent magnetic nanoparticles for in vivo targeted magnetofluorescent imaging of gastric cancer. J Nanobiotechnol 2011, 9:23.
14. Huang P., Li Z., Lin J., Yang D., Gao G., Xu C., et al. Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy. Biomaterials 2011, 32:3447-3458.
15. Nie S., Xing Y., Kim G.J., Simons J.W. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007, 9:257-288.
16. Bonoiu A.C., Mahajan S.D., Ding H., Roy I., Yong K.T., Kumar R., et al. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A 2009, 106:5546-5550.
17. Chen F., Huang P., Zhu Y.J., Wu J., Zhang C.L., Cui D.X. The photoluminescence, drug delivery and imaging properties of multifunctional Eu3t/Gd3t dual-doped hydroxyapatite nanorods. Biomaterials 2011, 32:9031-9039.
18. Park K., Lee S., Kang E., Kim K., Choi K., Kwon I.C. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv Funct Mater 2009, 19:1553-1566.
19. Liong M., Lu J., Kovochich M., Xia T., Ruehm S.G., Nel A.E., et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008, 2:889-896.
20. Derfus A.M., Chan W.C.W., Bhatia S.N. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2004, 4:11-18.
21. Singh R., Nalwa H.S. Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents, and anticancer nanodrugs. J Biomed Nanotechnol 2011, 7:489-503.
22. Medintz I.L., Uyeda H.T., Goldman E.R., Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005, 4:435-446.
23. Goldman E.R., Medintz I.L., Mattoussi H. Luminescent quantum dots in immunoassays. Anal Bioanal Chem 2006, 384:560-563.
24. Pathak S., Choi S.K., Arnheim N., Thompson M.E. Hydroxylated quantum dots as luminescent probes for in situ hybridization. J Am Chem Soc 2001, 123:4103-4104.
25. Mattheakis L.C., Dias J.M., Choi Y.J., Gong J., Bruchez M.P., Liu J., et al. Optical coding of mammalian cells using semiconductor quantum dots. Anal Biochem 2004, 327:200-208.
26. Clapp A.R., Medintz I.L., Mauro J.M., Fisher B.R., Bawendi M.G., Mattoussi H. Fluorescence resonance energy transfer between quantum dot donors and dye-labeled protein acceptors. J Am Chem Soc 2004, 126:301-310.
27. Willard D.M., Carillo L.L., Jung J., Van Orden A. CdSe-ZnS quantum dots as resonance energy transfer donors in a model protein-protein binding assay. Nano Lett 2001, 1:469-474.
28. Chan W.C., Maxwell D.J., Gao X., Bailey R.E., Han M., Nie S. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol 2002, 13:40-46.
29. Kong Y., Chen J., Gao F., Li W., Xu X., Pandoli O., et al. A multifunctional ribonuclease-A-conjugated CdTe quantum dot cluster nanosystem for synchronous cancer imaging and therapy. Small 2010, 6:2367-2373.
30. Newton D.L., Rybak S.M. Construction of ribonuclease-antibody conjugates for selective cytotoxicity. Methods Mol Med 2000, 25:27-35.
31. Kok R.J., Schraa A.J., Bos E.J., Moorlag H.E., Ásgeirsdóttir S.A., Everts M., et al. Preparation and functional evaluation of RGD-modified proteins as αvβ3 integrin directed therapeutics. Bioconjug Chem 2002, 13:128-135.
32. Furukawa T., Fu X., Kubota T., Watanabe M., Kitajima M., Hoffman R.M. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 1993, 53:1204-1208.
33. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
34. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
35. Chiou S.K., Jones M.K., Tarnawski A.S. Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 2003, 9:125-129.
36. Kroemer G., Martin S.J. Caspase-independent cell death. Nat Med 2005, 11:725-730.
37. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37:3-8.
38. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
39. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
40. Schuell B., Gruenberger T., Scheithauer W., Zielinski C., Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006, 6:123.
41. Eltze E., Wülfing C., Von Struensee D., Piechota H., Buerger H., Hertle L. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 2005, 26:1525-1531.
42. McKenzie S., DeSombre K., Bast B., Hollis D., Whitaker R., Berchuck A., et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 1993, 71:3942-3946.
43. Hetzel D.J., Wilson T.O., Keeney G.L., Roche P.C., Cha S.S., Podratz K.C. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992, 47:179-185.
44. Hirashima N., Takahashi W., Yoshii S., Yamane T., Ooi A. Protein overexpression and gene amplification of c-erbB-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001, 14:556-562.
45. Mitra A., Murty V., Pratap M., Sodhani P., Chaganti R. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994, 54:637-639.
46. Beckhardt R.N., Kiyokawa N., Xi L., Liu T.J., Hung M.C., El-Naggar A.K., et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995, 121:1265-1270.
47. Reichelt U., Duesedau P., Tsourlakis M.C., Quaas A., Link B.C., Schurr P.G., et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2006, 20:120-129.
48. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19:1523-1529.
49. Walberer M., Tschernatsch M., Fischer S., Ritschel N., Volk K., Friedrich C., et al. RNase therapy assessed by magnetic resonance imaging reduces cerebral edema and infarction size in acute stroke. Curr Neurovasc Res 2009, 6:12-19.
50. Altman S. RNA enzyme-directed gene therapy. Proc Natl Acad Sci U S A 1993, 90:10898-10900.
51. Lewin A.S., Hauswirth W.W. Ribozyme gene therapy: applications for molecular medicine. Trends Mol Med 2001, 7:221-228.
52. Iordanov M.S., Ryabinina O.P., Wong J., Dinh T.H., Newton D.L., Rybak S.M., et al. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 2000, 60:1983-1994.